1
|
Walker B, Jani CT, Liu W, Punjwani S, Kareff S, Ceglowski P, Singh H, Mariano M, Salciccioli JD, Borges L, Lopes G. Does a "Western Lifestyle" Confer a Higher Burden of Colorectal Cancer? A Comparison of EU15+ Countries versus Global Trends between 1990 and 2019. Cancers (Basel) 2024; 16:2277. [PMID: 38927980 PMCID: PMC11201493 DOI: 10.3390/cancers16122277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2024] [Revised: 06/10/2024] [Accepted: 06/17/2024] [Indexed: 06/28/2024] Open
Abstract
The incidence of colorectal cancer (CRC) in the U.S. is declining in adults 50 years and older; however, recent studies suggest an increasing disease burden among adults under age 50. This study aims to compare the incidence, mortality, and mortality-to-incidence ratios (MIRs) of CRC in EU15+ countries to determine if similar age-stratified occurrences are observed across these countries with similar "Western lifestyle"-related risk factors. Incidence and mortality rates for CRC between 1990 and 2019 were extracted using the Global Burden of Disease database. The data were age-stratified into groups between ages 25-49, 50-69, and greater than 69 years. We observed that the incidence of CRC increased globally for all age groups, with the highest increase observed for males (75.9%) and females (27.7%) aged 25-49. A similar trend was observed in 15 of the 19 EU15+ countries for males and 16 of the 19 EU15+ countries for females aged 25-49. Global mortality rates decreased for all age groups in females but increased for males in all age groups. This raises concerns regarding potentially modifiable risk factors contributing to increased CRC development and underscores the importance of implementing standardized screening at an earlier stage to ensure adequate detection in the younger population.
Collapse
Affiliation(s)
- Bradley Walker
- Department of Medicine, Mount Auburn Hospital, Cambridge, MA 02138, USA; (B.W.); (W.L.); (S.P.); (P.C.); (M.M.); (L.B.)
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Chinmay T. Jani
- Department of Medicine, Mount Auburn Hospital, Cambridge, MA 02138, USA; (B.W.); (W.L.); (S.P.); (P.C.); (M.M.); (L.B.)
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA; (S.K.); (G.L.)
| | - Weitao Liu
- Department of Medicine, Mount Auburn Hospital, Cambridge, MA 02138, USA; (B.W.); (W.L.); (S.P.); (P.C.); (M.M.); (L.B.)
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Shoheera Punjwani
- Department of Medicine, Mount Auburn Hospital, Cambridge, MA 02138, USA; (B.W.); (W.L.); (S.P.); (P.C.); (M.M.); (L.B.)
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Samuel Kareff
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA; (S.K.); (G.L.)
| | - Peter Ceglowski
- Department of Medicine, Mount Auburn Hospital, Cambridge, MA 02138, USA; (B.W.); (W.L.); (S.P.); (P.C.); (M.M.); (L.B.)
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Harpreet Singh
- Department of Pulmonary and Critical Care, Medical College of Wisconsin, Milwaukee, WI 53226, USA;
| | - Melissa Mariano
- Department of Medicine, Mount Auburn Hospital, Cambridge, MA 02138, USA; (B.W.); (W.L.); (S.P.); (P.C.); (M.M.); (L.B.)
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Justin D. Salciccioli
- Division of Pulmonary and Critical Care, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA;
| | - Lawrence Borges
- Department of Medicine, Mount Auburn Hospital, Cambridge, MA 02138, USA; (B.W.); (W.L.); (S.P.); (P.C.); (M.M.); (L.B.)
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
- Division of Gastroenterology, Mount Auburn Hospital, Cambridge, MA 02138, USA
| | - Gilberto Lopes
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA; (S.K.); (G.L.)
| |
Collapse
|
2
|
Safiri S, Hassanzadeh K, Ghaffari Jolfayi A, Mousavi SE, Motlagh Asghari K, Nejadghaderi SA, Naghdi-Sedeh N, Noori M, Sullman MJM, Collins GS, Kolahi AA. Kidney cancer in the Middle East and North Africa region: a 30-year analysis (1990-2019). Sci Rep 2024; 14:13710. [PMID: 38877130 PMCID: PMC11178886 DOI: 10.1038/s41598-024-64521-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Accepted: 06/10/2024] [Indexed: 06/16/2024] Open
Abstract
Kidney cancer, a type of urogenital cancer, imposes a high burden on patients. Despite this, no recent research has evaluated the burden of this type of cancer in the Middle East and North Africa (MENA) region. This study explored the burden of kidney cancer from 1990 to 2019 according to age, sex and socio-demographic index (SDI). The Global Burden of Disease (GBD) 2019 data was utilized to estimate the incidence, death, and disability-adjusted life-years (DALYs) caused by kidney cancer. These estimates were reported as counts and as age-standardised rates with 95% uncertainty intervals (UIs). The estimated age-standardised incidence, mortality, and DALY rates of kidney cancer in 2019 were 3.2 (2.8-3.6), 1.4 (1.2-1.6), and 37.2 (32.0-42.6) per 100,000, respectively. Over the period from 1990 to 2019, these rates have increased by 98.0%, 48.9%, and 37.7%, respectively. In 2019, the United Arab Emirates, Qatar, and Lebanon had the largest age-standardised incidence, mortality, and DALY rates. The smallest age-standardised incidence rates were seen in Yemen, Afghanistan, and the Syrian Arab Republic. Additionally, the smallest age-standardised mortality and DALY rates were observed in the Syrian Arab Republic, Yemen, and Morocco. The highest incidence rates were found among individuals aged 75-79 in both males and females. In 2019, the MENA/Global DALY ratio exceeded one for females aged 5-19 age and males aged 5-14, compared to 1990age groups in males. The burden of kidney cancer consistently rose with increasing SDI levels from 1990 to 2019. The increasing burden of kidney cancer highlights the urgent need for interventions aimed at improving early diagnosis and treatment in the region.
Collapse
Affiliation(s)
- Saeid Safiri
- Social Determinants of Health Research Center, Department of Community Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
- Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
| | - Kamaleddin Hassanzadeh
- Department of Urology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Amir Ghaffari Jolfayi
- Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Seyed Ehsan Mousavi
- Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
- Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Kimia Motlagh Asghari
- Social Determinants of Health Research Center, Department of Community Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Seyed Aria Nejadghaderi
- HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
- Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| | - Nima Naghdi-Sedeh
- Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Maryam Noori
- Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Mark J M Sullman
- Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus
- Department of Social Sciences, University of Nicosia, Nicosia, Cyprus
| | - Gary S Collins
- Centre for Statistics in Medicine, NDORMS, Botnar Research Centre, University of Oxford, Oxford, UK
- NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Ali-Asghar Kolahi
- Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
3
|
Cayuela L, Font González R, Lendínez-Cano G, Medina-López R, Cayuela A. The influence of age, period, and cohort factors on the incidence of kidney cancer in Spain 1990-2019: Evidence from the global burden of disease study. Actas Urol Esp 2024:S2173-5786(24)00057-X. [PMID: 38599570 DOI: 10.1016/j.acuroe.2024.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Accepted: 02/19/2024] [Indexed: 04/12/2024]
Abstract
OBJECTIVE This study aimed to assess the influence of age, period, and cohort (A-P-C) factors on kidney cancer (KC) incidence trends in Spain from 1990 to 2019. METHODS Employing data from the Global Burden of Disease Study 2019, we employed joinpoint analysis to determine long-term patterns and A-P-C modelling to quantify net drift, local drift, longitudinal age curves, and rate ratios (RRs) of period and cohort effects. RESULTS Over the period 1990-2019, an estimated 142,811 cases of KC were diagnosed in Spain. A consistent upward trend in KC incidence was observed for both men and women, with the male-to-female ratio remaining stable at 2.6. Joinpoint analysis identified three distinct periods for men: An initial period (1990-1995) characterised by a significant increase in rates, a subsequent period (1995-2016) characterised by a slowdown in the rate of increase, and a final period (2016-2019) in which rates have plateaued. In women, 2 time periods were observed: an initial period (1990-2007) in which rates increased significantly, followed by a period of stabilization (2007-2019). Men born in the early-mid 20th century had a rising KC risk, peaking in the 1960s. Women's risk rose steadily, peaking in the late 1990s. CONCLUSION A-P-C analysis reveals steady KC incidence increase in both genders over three decades. This highlights the need for targeted public health policies and effective prevention strategies.
Collapse
Affiliation(s)
- L Cayuela
- Servicio de Medicina Interna, Hospital Severo Ochoa, Leganés, Spain
| | - R Font González
- Servicio de Medicina Interna, Hospital Severo Ochoa, Leganés, Spain
| | - G Lendínez-Cano
- Unidad de Nefrología y Urología, Unidad de Uro-oncología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - R Medina-López
- Unidad de Nefrología y Urología, Unidad de Uro-oncología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - A Cayuela
- Unidad de Salud Pública, Prevención y Promoción de la Salud, Área de Gestión Sanitaria Sur de Sevilla, Sevilla, Spain.
| |
Collapse
|
4
|
Jani CT, Ahmed A, Singh H, Mouchati C, Al Omari O, Bhatt PS, Sharma R, Farooq M, Liu W, Shalhoub J, Marshall D, Salciccioli JD, Warner JL, Lam P. Burden of AML, 1990-2019: Estimates From the Global Burden of Disease Study. JCO Glob Oncol 2023; 9:e2300229. [PMID: 37992271 PMCID: PMC10681472 DOI: 10.1200/go.23.00229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 09/17/2023] [Accepted: 10/10/2023] [Indexed: 11/24/2023] Open
Abstract
PURPOSE AML accounts for 80% of acute leukemia in adults. While progress has been made in treating younger patients in the past 2 decades, there has been limited improvement for older patients until recently. This study examines the global and European Union (EU) 15+ trends in AML between 1990 and 2019. METHODS We extracted age-standardized incidence rates (ASIRs), age-standardized death rates (ASMRs), and disability-adjusted life years, stratified by sex from the Global Burden of Disease Study database, and mortality-to-incidence ratio (MIR) were computed. Trends were compared using Joinpoint regression. RESULTS The findings show a global increase in AML incidence for both sexes from 1990 to 2019. In the EU15+ countries, most countries exhibited an increase in ASIR for both sexes. Joinpoint revealed that globally for male patients, ASIR steadily increased until 2010, remained stable until 2015 followed by a decline till 2019. Similar trends were observed in female patients. For ASMR, although there was an increase globally and in most EU15+ countries, there was a statistically significant decrease in mortality rates globally and in the majority of EU15+ countries in recent years. MIR improved in both sexes globally. On age stratification, AML burden was highest among older groups (55 years and older), while the lowest rates were observed in younger than 20 years. CONCLUSION The findings from our study indicate a global rise in AML incidence and mortality in both sexes and decrease in MIR from 1990 to 2019 suggesting a better survival. However, on Joinpoint analysis, there is no change in MIR in women in the past decade and past 4 years in men indicating plateau in survival trends despite recent advances.
Collapse
Affiliation(s)
- Chinmay T. Jani
- Sylvester Comprehensive Cancer Center at University of Miami, Miami, FL
- Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
- Department of Medicine, Harvard Medical School, Boston, MA
- M.D.R Collaborative Group, London, United Kingdom
| | - Alaaeldin Ahmed
- Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
- Department of Medicine, Harvard Medical School, Boston, MA
- M.D.R Collaborative Group, London, United Kingdom
| | - Harpreet Singh
- M.D.R Collaborative Group, London, United Kingdom
- Department of Pulmonary and Critical Care, Medical College of Wisconsin, Milwaukee, WI
| | - Christian Mouchati
- M.D.R Collaborative Group, London, United Kingdom
- Department of Neurology, Cleveland Clinic, Cleveland, OH
| | - Omar Al Omari
- Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
- Department of Medicine, Harvard Medical School, Boston, MA
- M.D.R Collaborative Group, London, United Kingdom
- Department of Pulmonary and Critical Care, Temple University, Philadelphia, PA
| | - Padmanabh S. Bhatt
- Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
- Department of Medicine, Harvard Medical School, Boston, MA
- M.D.R Collaborative Group, London, United Kingdom
| | - Rajesh Sharma
- Humanities and Social Science, National Institute of Technology Kurukshetra, Haryana, India
| | | | - Weitao Liu
- Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
- Department of Medicine, Harvard Medical School, Boston, MA
| | - Joseph Shalhoub
- M.D.R Collaborative Group, London, United Kingdom
- Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, United Kingdom
| | - Dominic Marshall
- M.D.R Collaborative Group, London, United Kingdom
- Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
| | - Justin D. Salciccioli
- Department of Medicine, Harvard Medical School, Boston, MA
- M.D.R Collaborative Group, London, United Kingdom
- Department of Pulmonary and Critical Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Jeremy L. Warner
- Center for Clinical Cancer Informatics and Data Science, Legorreta Cancer Center, Brown University, Providence, RI
- Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI
| | - Prudence Lam
- Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
- Department of Medicine, Harvard Medical School, Boston, MA
- Division of Hematology and Oncology, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
| |
Collapse
|
5
|
Jani CT, Singh H, Abdallah N, Mouchati C, Arora S, Kareff S, Salciccioli J, Thomson CC, Velcheti V. Trends in Lung Cancer Incidence and Mortality (1990-2019) in the United States: A Comprehensive Analysis of Gender and State-Level Disparities. JCO Glob Oncol 2023; 9:e2300255. [PMID: 38127772 PMCID: PMC10752493 DOI: 10.1200/go.23.00255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 09/13/2023] [Accepted: 10/10/2023] [Indexed: 12/23/2023] Open
Abstract
PURPOSE Lung cancer is the leading cause of cancer-related deaths in the United States. This study aims to analyze lung cancer incidence, mortality, and related statistics from 1990 to 2019, focusing on national- and state-level trends and exploring potential disparities between sexes. METHODS The Global Burden of Disease database was used to extract tracheal, bronchus, and lung cancer mortality data from 1990 to 2019 for both males and females and across all states of the United States. Age-standardized incidence rates, age-standardized mortality rates, disability-adjusted life years (DALYs), and mortality-to-incidence indices (MIIs) were studied to assess for gender-based, geographic, and temporal disparities. Joinpoint regression analysis was performed to further evaluate trends. RESULTS The incidence of these cancers in the United States decreased between 1990 and 2019 by 23.35%, with a more significant decline in males (37.73%) than females (1.41%). Similarly, for mortality, a decrease was observed for both sexes combined (26.83%), but much more significantly for males (40.23%) than females (6.01%). The MIIs decreased overall, but there were variations across states. DALYs decreased for both sexes combined, with males experiencing a larger reduction, but an increase was noted in some states for females. CONCLUSION This analysis reveals diverse trends pertaining to the incidence, mortality, and disability burden associated with lung cancer by sex and states in the United States, emphasizing the need for targeted interventions to reduce disparities. These findings contribute to our understanding of the current landscape of lung cancer and can inform future strategies for prevention, early detection, and management.
Collapse
Affiliation(s)
- Chinmay T. Jani
- Sylvester Comprehensive Cancer Center at University of Miami, Miami, FL
- MDR Collaborative Group, London, United Kingdom
- Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
| | - Harpreet Singh
- MDR Collaborative Group, London, United Kingdom
- Medical College of Wisconsin, Milwaukee, WI
| | - Nour Abdallah
- MDR Collaborative Group, London, United Kingdom
- Cleveland Clinic, Cleveland, OH
| | - Christian Mouchati
- MDR Collaborative Group, London, United Kingdom
- Case Western Reserve University School of Medicine, Cleveland, OH
| | - Shreya Arora
- MDR Collaborative Group, London, United Kingdom
- Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
| | - Samuel Kareff
- Sylvester Comprehensive Cancer Center at University of Miami, Miami, FL
| | - Justin Salciccioli
- MDR Collaborative Group, London, United Kingdom
- Brigham and Women's Hospital—Harvard Medical School, Boston, MA
| | | | | |
Collapse
|
6
|
Xu Q, Zhang T, Xia T, Jin B, Chen H, Yang X. Epidemiological Trends of Kidney Cancer Along with Attributable Risk Factors in China from 1990 to 2019 and Its Projections Until 2030: An Analysis of the Global Burden of Disease Study 2019. Clin Epidemiol 2023; 15:421-433. [PMID: 37013109 PMCID: PMC10066698 DOI: 10.2147/clep.s400646] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2023] [Accepted: 03/15/2023] [Indexed: 03/30/2023] Open
Abstract
Background Understanding the past and future burden of kidney cancer in China over years provides essential references for optimizing the prevention and management strategies. Methods The data on incidence, mortality, disability-adjusted life-years (DALYs) and age-standardized rates of kidney cancer in China, 1990-2019, were collected from the database of Global Burden of Disease Study 2019. The estimated annual percentage change (EAPC) was calculated to depict the trends of kidney cancer burden, and Bayesian age-period-cohort analysis was used to predict the incidence and mortality in the next decade. Results Over the past 30 years, the number of new kidney cancer cases sharply increased from 11.07 thousand to 59.83 thousand, and the age-standardized incidence rate (ASIR) tripled from 1.16/100,000 to 3.21/100,000. The mortality and DALYs also presented an increasing pattern. Smoking and high body mass index were mainly risk factors for kidney cancer. We predicted that by 2030, the incident cases and deaths of kidney cancer would increase to 126.8 thousand and 41.8 thousand, respectively. Conclusion In the past 30 years, the kidney cancer burden gradually increased in China, and it will continue to rise in the next decade, which reveals more targeted intervention measures are necessary.
Collapse
Affiliation(s)
- Qianqian Xu
- Department of Organ Transplantation, Qilu Hospital of Shandong University, Jinan, 250012, People’s Republic of China
- The Key Laboratory of Infection and Immunity of Shandong Province, Department of Pharmacology, School of Basic Medical Science, Shandong University, Jinan, 250012, People’s Republic of China
| | - Tingxiao Zhang
- Organ Transplant Department, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, People’s Republic of China
| | - Tong Xia
- Organ Transplant Department, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, People’s Republic of China
| | - Bin Jin
- Department of Organ Transplantation, Qilu Hospital of Shandong University, Jinan, 250012, People’s Republic of China
- Department of Hepatobiliary Surgery, General Surgery, The Second Hospital of Shandong University, Jinan, 250033, People’s Republic of China
| | - Hui Chen
- Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People’s Republic of China
- Clinical Research Center of Shandong University, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, People’s Republic of China
| | - Xiaorong Yang
- Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People’s Republic of China
- Clinical Research Center of Shandong University, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, People’s Republic of China
- Correspondence: Xiaorong Yang, Clinical Epidemiology Unit, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Lixia District, Jinan, 250012, People’s Republic of China, Tel +86 53182166951, Email
| |
Collapse
|